A majority of states cover HPV vaccination through age 45 years with no need for prior authorization, which has implications for adults with certain dermatologic diseases. DermTwitter
"may be at increased risk for persistent and high-risk HPV infection...and may benefit from vaccination," they added. However, the details of Medicaid insurance coverage for the vaccine in adults at risk have not been explored, so the researchers examined Medicaid policies for coverage of the vaccine for adults aged 27-45 years as a proxy for coverage of the insured adult population in the United States. They collected data from Sept. 14 through Dec. 8, 2021.
The study findings were limited by the use of Medicaid coverage only, the researchers noted. Consequently, patients eligible for HPV vaccination who are uninsured or have other types of insurance may face additional barriers in the form of high costs, given that the current retail price is $250-$350 per shot for the three-shot series, the researchers noted.
"Vaccines can be cost-prohibitive for patients without insurance coverage, so we hope that dermatologists will be more likely to recommend the HPV vaccine to patients 27-45 years of age if they know that it is likely covered by insurance," Noe noted. Looking ahead, she said that"additional research is necessary to create vaccine guidelines specific to dermatology patients and dermatology medications, so we can provide clear recommendations to our patients and ensure appropriate insurance coverage for all necessary vaccines.", of the department of dermatology, George Washington University, Washington, who was asked to comment on the study.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
South Dakota Approved Medicaid Expansion, But Implementation May Not Be EasySouth Dakotans overwhelmingly voted to expand Medicaid, but conservative state politicians may put up road blocks.
Consulte Mais informação »
Experimental Cancer Vaccine Yields Promising Results: NIH Finds Significant Tumor RegressionNIH scientists find that IV administration improves tumor-fighting action. An experimental therapeutic cancer vaccine induced two distinct and desirable immune system responses that led to significant tumor regression in mice. This is according to a new research study published in the journal Cell,
Consulte Mais informação »
Seniors may have difficulty finding proper flu vaccine this seasonSome older Alabamians may have a more difficult time finding the appropriate flu vaccine this season.
Consulte Mais informação »
Seniors may have difficulty finding proper flu vaccine this seasonSome older Alabamians may have a more difficult time finding the appropriate flu vaccine this season.
Consulte Mais informação »
Germany's BioNTech says to set up mRNA vaccine facility in SingaporeBioNTech SE , the German biotech that developed a widely used COVID-19 vaccine with Pfizer Inc , acquired a manufacturing facility in Singapore, its first in Asia, the company said on Monday.
Consulte Mais informação »